Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17434126 | 0.87 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL6744766 | 0.83 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL22766174 | 0.83 | KDM1A (0.31) | — | |
| SCHEMBL2002035 | 0.82 | MEN1 (0.36) | MEN1KMT2APDE2A | |
| SCHEMBL25015121 | 0.82 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL31582913 | 0.82 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL3841835 | 0.80 | PDE2A (0.33) | MEN1KMT2APDE2A | |
| SCHEMBL22331229 | 0.78 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL30662731 | 0.78 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL3093413 | 0.77 | MEN1 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-115427035-B | ENL/AF9 YEATS inhibitors | 洛克菲勒大学 | 2025-04-22 | — | — | CN | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| US-12071424-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| CN-111566089-B | IRE1 small molecule inhibitors | 康奈尔大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| WO-2019021208-A1 | INDAZOLE DERIVATIVES USEFUL AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | WO | disclosed |
| US-9556135-B2 | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | AMGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-3019487-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-9199963-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2015005489-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014059185-A1 | AMINO - DIHYDROTHIAZINE AND AMINO - DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | AMGEN INC. | 2014-04-17 | — | — | US | disclosed |
| WO-2012095781-A1 | INDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095781-A1 | INDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | MEN1 3601/4885KMT2A 2312/4885PDE2A 3888/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | MEN1 3601/4885KMT2A 2312/4885PDE2A 3888/4885 |
| US-12071424-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | MEN1 3601/4885KMT2A 2312/4885PDE2A 3888/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | MEN1 4738/4885KMT2A 4409/4885PDE2A 2781/4885 |
| US-20140107109-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | MEN1 4597/4885KMT2A 2887/4885PDE2A 1512/4885 |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | CTPS1, CTPS2, ECHS1 | MEN1 4328/4885KMT2A 3259/4885PDE2A 2577/4885 |
| US-20150259308-A1 | AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE | BACE1, BACE2, APP | MEN1 4597/4885KMT2A 2887/4885PDE2A 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.